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The extent of bioactivation of the herbal constituent estragole to
its ultimate carcinogenic metabolite 1#-sulfooxyestragole depends
on the relative levels of bioactivation and detoxification pathways.
The present study investigated the kinetics of the metabolic
reactions of both estragole and its proximate carcinogenic
metabolite 1#-hydroxyestragole in humans in incubations with
relevant tissue fractions. Based on the kinetic data obtained
a physiologically based biokinetic (PBBK) model for estragole in
human was defined to predict the relative extent of bioactivation
and detoxification at different dose levels of estragole. The
outcomes of the model were subsequently compared with those
previously predicted by a PBBK model for estragole in male rat to
evaluate the occurrence of species differences in metabolic
activation. The results obtained reveal that formation of 1#-
oxoestragole, which represents a minor metabolic route for
1#-hydroxyestragole in rat, is the main detoxification pathway of
1#-hydroxyestragole in humans. Due to a high level of this 1#-
hydroxyestragole oxidation pathway in human liver, the predicted
species differences in formation of 1#-sulfooxyestragole remain
relatively low, with the predicted formation of 1#-sulfooxyestra-
gole being twofold higher in human compared with male rat, even
though the formation of its precursor 1#-hydroxyestragole was
predicted to be fourfold higher in human. Overall, it is concluded
that in spite of significant differences in the relative extent of
different metabolic pathways between human and male rat there
is a minor influence of species differences on the ultimate overall
bioactivation of estragole to 1#-sulfooxyestragole.
Key Words: estragole; PBBK; human; metabolism; in vitro;
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Estragole is an alkenylbenzene that occurs naturally in
certain herbs such as tarragon, basil, and fennel, and in
essential oils of these herbs used as flavoring agents (Smith
et al., 2002). At high dose levels this compound is found to be
hepatocarcinogenic in different rodents (Drinkwater et al.,
1976; Miller et al., 1983; Wiseman et al., 1987). Uncertainties
about the shape of the dose-response curve at dose levels
relevant for dietary human intake and about species differences
in metabolism and metabolic activation make it difficult to
extrapolate the cancer risk from high dose animal experiments
to the low dose human situation. In an evaluation performed by
the expert panel of the Flavor and Extract Manufacturers
Association (FEMA) it was concluded that exposure to
estragole from herbs, essential oils, and flavor substances does
not pose a significant cancer risk to humans (Smith et al.,
2002). In this conclusion, experimental data that suggested
a nonlinear relationship between dose and profiles of
metabolism and metabolic activation were taken into account.
The FEMA expert panel estimated the average daily intake of
estragole to be less than 0.01 mg/kg bw/day, which was
determined based on production volume data for flavor use
(Smith et al., 2002). The Scientific Committee on Food
(SCF) of the European Union concluded in their evaluation of
estragole, that estragole is genotoxic and carcinogenic,
and restrictions in use levels were indicated (SCF, 2001).
The SCF estimated the average daily intake of estragole from
all food sources to be 4.3 mg/day, corresponding to ~0.07 mg/
kg bw/day for a 60 kg person (SCF, 2001). This estimation is
based on theoretical maximum use levels of estragole in
various food categories and consumption data for these food
categories.
Rodent carcinogenicity of estragole has been linked to its
metabolic conversion to a genotoxic metabolite (Drinkwater
et al., 1976; Miller et al., 1983; Wiseman et al., 1987).
Bioactivation of estragole starts with the conversion of
estragole into the proximate carcinogenic metabolite 1#-
hydroxyestragole (Fig. 1), which is mainly catalyzed by
cytochrome P450 1A2 and P450 2A6 (Jeurissen et al., 2007).
Other phase I metabolic pathways represented in Figure 1
include O-demethylation, epoxidation, and 3#-hydroxylation of
estragole, leading to the formation of, respectively,
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4-allylphenol, estragole-2#,3#-oxide, and 3#-hydroxyanethole.
These metabolic pathways result in detoxification of estragole
(Anthony et al., 1987; Guenthner and Luo, 2001; Luo et al.,
1992; Phillips et al., 1981; Sangster et al., 1987; Solheim and
Scheline, 1973). Sulfonation of 1#-hydroxyestragole leads to
the formation of the ultimate carcinogenic metabolite, which is
unstable and degrades in aqueous environment to a reactive
carbocation that is capable of forming DNA adducts (Phillips
et al., 1981, 1984; Randerath et al., 1984; Wiseman et al.,
1985). Conjugation of 1#-hydroxyestragole with glucuronic
acid results in detoxification of 1#-hydroxyestragole, because it
results in formation of a stable metabolite that has been
detected in the urine of both humans and rats exposed to
estragole (Anthony et al., 1987; Sangster et al., 1987). In
addition to glucuronidation and sulfonation, oxidation of 1#-
hydroxyestragole to 1#-oxoestragole has been reported as
a possible metabolic route of 1#-hydroxyestragole (Solheim
and Scheline, 1973). The 1#-oxoestragole metabolite of 1#-
hydroxyestragole is a reactive metabolite that has been shown
to be able to form adducts with 2#-deoxyguanosine in a direct
reaction with this nucleoside (Phillips et al., 1981). In spite of
this, 1#-oxoestragole was not carcinogenic in vivo in mice
(Wiseman et al., 1987). This has been ascribed to extensive
detoxification of 1#-oxoestragole via conjugation with gluta-
thione or endogenous amines (Fennell et al., 1984; Wiseman
et al., 1987; Wislocki et al., 1977). To date, formation of 1#-
oxoestragole has been considered to be of minor importance,
because only relatively small amounts of derivatives of this
metabolite have been detected in the urine of rats exposed
orally to [methoxy-14C]-labeled estragole (Solheim and
Scheline, 1973).
Dose-dependent effects in metabolism of estragole have
been revealed in both rats and mice exposed to different oral
doses of estragole. In these species the relative extent of
O-demethylation decreased with increasing doses accompanied
by a relative increase in excretion of 1#-hydroxyestragole
glucuronide in the urine (Anthony et al., 1987; Zangouras
et al., 1981). Based on a previously constructed physiologically
based biokinetic (PBBK) model for estragole in male rat (Punt
et al., 2008) it was demonstrated that these dose-dependent
effects could be explained by a shift in metabolism of estragole.
At low oral doses, O-demethylation is the major metabolic
FIG. 1. Metabolism of estragole.
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pathway, occurring mainly in the lung and kidney due to
formation of this metabolite with high affinity in these organs.
Saturation of this metabolic pathway in the lung and kidney at
increasing oral dose levels, leads to a relative increase in
formation of 1#-hydroxyestragole in the liver and a concomitant
increase in formation of 1#-hydroxyestragole glucuronide and
the ultimate carcinogenic metabolite, 1#-sulfooxyestragole.
Such dose-dependent effects can have consequences for the
extrapolation of the cancer risk from high dose animal
experiments to humans at relevant dietary intake levels.
In addition to dose-dependent effects, species differences in
metabolism and metabolic activation can also occur. We have,
for instance, previously demonstrated that male rats are more
efficient in sulfonation of 1#-hydroxyestragole than humans
(Punt et al., 2007). To determine the overall differences
between humans and male rats in bioactivation of estragole, it
is of importance to compare the relative extent of different
metabolic pathways between these species. The present study
investigated the kinetics of possible metabolic reactions of
estragole and 1#-hydroxyestragole in humans in incubations
with relevant human tissue fractions. The kinetic data obtained
were used to build a PBBK model for estragole metabolism in
human to predict the relative extent of bioactivation and
detoxification of estragole at dose levels relevant for dietary
human intake. An evaluation of the model defined was
performed by comparing the predicted formation of 4-
allylphenol and 1#-hydroxyestragole glucuronide to literature
reported levels of these metabolites in humans exposed to
estragole (Sangster et al., 1987). The outcomes of the model
were subsequently compared with those of the previously
defined PBBK model for estragole in male rat to evaluate the
occurrence of species differences in metabolic activation and
detoxification of estragole.
MATERIALS AND METHODS
Chemicals and biological materials. Pooled, mixed gender human lung,
kidney, and small intestine microsomes were purchased from BioPredic
International (Rennes, France). Pooled, mixed gender human liver S9 and
microsomes were purchased from BD Gentest (Woburn, MA). Hydrochloric
acid (37%) was purchased from Merck (Darmstadt, Germany). b-Glucuroni-
dase, nicotinamide adenine dinucleotide phosphate (reduced) (NADPH), and
NADþ were obtained from Roche Diagnostics (Mannheim, Germany).
Tris(hydroxymethyl)aminomethane was obtained from Gibco BRL Life
Technologies (Paisley, UK). Estragole (4-allylanisol), acetonitrile (chromatog-
raphy grade), methanol, dimethylsulfoxide (DMSO), ascorbic acid, alamethi-
cin, glutathione (GSH), bovine serum albumin (BSA), uridine 5#-
diphosphoglucuronic acid (UDPGA), and a GSH assay kit were purchased
from Sigma-Aldrich (Steinheim, Germany). 1#-Hydroxyestragole, 4-allylphe-
nol, estragole-2#,3#-oxide, and 3#-hydroxyanethole were synthesized as
described previously (Punt et al., 2008). Caution: 1#-hydroxyestragole, 3#-
hydroxyanethole, estragole-2#,3#-oxide, 1#-oxoestragole are genotoxic and
should be handled accordingly.
Phase I metabolism. Mixed gender human liver, lung, kidney, and small
intestine microsomal preparations were incubated with estragole in the presence
of NADPH, to identify the organs involved in the phase I metabolism of
estragole. The incubation mixtures had a final volume of 100 ll, containing
(final concentrations) 3mM NADPH, 1mM ascorbic acid and 1 mg/ml
microsomal protein in 0.2M Tris-HCl (pH 7.4). After preincubating at 37C for
1 min, the reactions were started by adding the substrate estragole. Initial
incubations with the different microsomal fractions were performed at
a substrate concentration of 100lM (final concentration) at several incubation
times. The reactions were terminated by addition of 25 ll cold acetonitrile.
Additional incubations to determine the kinetic constants for the formation of
phase I metabolites of estragole were performed only with human liver
microsomes, because these were the microsomal samples tested that resulted in
metabolic conversion of estragole (see Results section). These incubations were
carried out for 10 min at a substrate concentration that ranged from 10 to
400lM estragole. Under these conditions the formation of the different
estragole metabolites was linear with time and microsomal protein concentra-
tion. All samples were centrifuged for 5 min at 16,000 3 g and 50 ll of the
supernatant of each sample was analyzed by high-performance liquid
chromatography (HPLC)-UV as described previously (Punt et al., 2008). In
the blank incubations performed without NADPH low amounts of 3#-
hydroxyanethole were formed, corresponding to approximately 0.6% of the
applied concentration of estragole. For this reason the formation of 3#-
hydroxyanethole was corrected for the amount of 3#-hydroxyanethole formed
in the blank incubations. 3#-Hydroxyanethole was quantified by comparison of
the peak areas of the metabolite in the chromatograms obtained at a wavelength
of 206 nm to the calibration curve of the synthesized metabolite. Formation of
4-allylphenol and 1#-hydroxyestragole were quantified by comparison of the
peak areas of the different metabolites in the chromatograms obtained at
a wavelength of 225 nm to the calibration curve of the corresponding
synthesized metabolites. Quantification of estragole-2#,3#-diol, which reflects
formation of estragole-2#,3#-oxide (see Results section), was achieved by
comparison of the peak area of estragole-2#,3#-diol in the chromatograms
obtained at a wavelength of 225 nm to the calibration curve of estragole-2#,3#-
oxide, because estragole-2#,3#-diol has a similar molar extinction coefficient as
estragole-2#,3#-oxide (Punt et al., 2008).
Glucuronidation of 1#-hydroxyestragole. Mixed gender human liver
microsomal preparations were incubated with 1#-hydroxyestragole in the
presence of UDPGA. The incubation mixtures had a final volume of 200 ll,
containing (final concentrations) 10mM UDPGA, and 1 mg/ml microsomal
protein in 0.2M Tris-HCl (pH 7.4) containing 10mM MgCl2. The incubation
mixtures were pre-treated on ice with 0.025 mg/ml of the poreforming peptide
alamethicin from a 200 times concentrated stock solution in methanol for 15
min to overcome enzyme latency and obtain maximal glucuronidation activity
(Fisher et al., 2000; Lin and Wong, 2002). The reactions were started by the
addition of the substrate 1#-hydroxyestragole from a 200 times concentrated
stock solution in DMSO, after preincubating at 37C for 1 min. The kinetic
constants for glucuronidation of 1#-hydroxyestragole were determined at
substrate concentrations that ranged from 50 to 2000lM 1#-hydroxyestragole.
The reactions were terminated after 360 min by addition of 50 ll cold
acetonitrile. Under these conditions glucuronidation of 1#-hydroxyestragole
was linear with time and microsomal protein concentration. All samples were
centrifuged for 5 min at 16,0003 g and 50 ll of the supernatant of each sample
was analyzed by HPLC as described previously (Punt et al., 2008). Formation
of 1#-hydroxyestragole glucuronide in these incubations was verified by
treatment of samples with b-glucuronidase and analysis of samples by liquid
chromatography mass spectrometry (LC-MS) as described previously (Punt
et al., 2008). No synthetic standard of 1#-hydroxyestragole glucuronide was
available for quantification of this conjugate. Because 1#-hydroxyestragole
glucuronide has the same UV spectrum as 1#-hydroxyestragole (data not
shown) it was assumed that it has the same molar extinction coefficient as 1#-
hydroxyestragole, allowing quantification of this metabolite by comparison of
the peak area of 1#-hydroxyestragole glucuronide in the chromatograms
obtained at a wavelength of 225 nm to the calibration curve of 1#-
hydroxyestragole. This calibration curve was prepared with the synthesized
1#-hydroxyestragole, which was analyzed by HPLC on an Alltima C18 5-lm
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column, 150 mm 3 4.6 mm (Alltech, Breda, The Netherlands) coupled to
a Waters 2695 alliance HPLC system (Waters, Etten-Leur, the Netherlands). An
isocratic mobile phase gradient was applied consisting of 25% acetonitrile and
75% ultrapure water containing 0.1% (vol/vol) acetic acid.
Oxidation of 1#-hydroxyestragole. Formation of 1#-oxoestragole was
analyzed in incubations with both human and male rat liver microsomes, using
NADþ as cofactor and GSH to trap the transient 1#-oxoestragole. The kinetic
constants for formation of the 1#-oxoestragole adduct with glutathione,
reflecting the formation of 1#-oxoestragole were determined with human but
also with male rat liver microsomes at substrate concentrations that ranged from
10 to 1000lM 1#-hydroxyestragole. These incubation mixtures had a final
volume of 100 ll, containing (final concentrations) 3mM NADþ, 2mM GSH,
and 1 mg/ml microsomal protein in 0.2M Tris-HCl (pH 7.4). The reactions
were terminated after 10 min by addition of 25 ll cold acetonitrile. Under these
conditions the formation of the glutathione adduct, 3#-(glutathion-S-yl)-1#-oxo-
2#-3#-dihydroestragole (GS-1#-oxoestragole), was linear with time and
microsomal protein concentration. The level of GSH in the incubations was
optimized to obtain maximum scavenging of 1#-oxoestragole. To this end
incubations were performed in the presence of increasing concentrations of
GSH, ranging from 2 to 10mM. At a concentration of 2mM GSH maximum
formation of GS-1#-oxoestragole was reached in the incubations, pointing at
maximum scavenging of 1#-oxoestragole at this concentration.
Due to the presence of microsomal protein in the incubations the maximum
formation of GS-1#-oxoestragole could be affected by providing an alternative
reaction possibility for the reactive 1#-oxoestragole. Experiments, in which the
protein content was increased by addition of BSA revealed, however, no
decrease in formation of GS-1#-oxoestragole, indicating that at a level of 1 mg/
ml microsomal protein the protein content does not significantly decrease GS-
1#-oxoestragole formation (data not shown).
For HPLC analysis the samples were centrifuged for 5 min at 16,000 3 g
and 50 ll of the supernatant of each sample was analyzed on an Alltima C18
5-lm column, 150 mm x 4.6 mm (Alltech) coupled to a Waters 2695 alliance
HPLC system (Waters). The gradient was made with acetonitrile and ultrapure
water containing 0.1% (vol/vol) acetic acid. The flow rate was 1 ml/min and
a gradient was applied from 0 to 25% acetonitrile over 5 min, after which the
percentage of acetonitrile was kept at 25% for 5 min and then increased to
100% over 2 min. Detection was performed at 280 nm using a Waters 2996
photodiode array detector (Waters).
Formation of GS-1#-oxoestragole in the incubations was verified by LC-MS,
which was performed on a Finnigan Surveyor HPLC system coupled to an
LXQ mass spectrometer (Thermo Finnigan, San Jose, CA). Aliquots of 20 ll
(injected volume) were separated on an Alltima C18 5-lm column, 150 x
2.1 mm (Alltech). The gradient was made with acetonitrile and ultra pure water
containing 0.1% (vol/vol) acetic acid and the flow rate was set to 0.1 ml/min.
A linear gradient was applied from 0 to 25% acetonitrile over 5 min and was
kept at 25% for 5 min, after which the percentage of acetonitrile was increased
to 100% over 2 min. Mass spectrometric analysis was performed in positive
electrospray mode using a spray voltage of 5 kV, a capillary temperature of
275C, and nitrogen as sheath gas (60 arbitrary units). Full scan data (m/z 125–
500) were obtained to identify the main protonated molecular ion (MHþ)
present in the sample.
Quantification of GS-1#-oxoestragole was performed by means of
a calibration curve. To this end GS-1#-oxoestragole was synthesized as
a reference compound from 1#-oxoestragole and GSH based on the protocol of
Phillips et al. (1981). 1#-Oxoestragole was synthesized from 1#-hydroxyestra-
gole as described for 1#-oxosafrole by Fennell et al. (1984). A calibration curve
of GS-1#-oxoestragole was prepared by incubating 40lM 1#-oxoestragole with
different concentrations of GSH, ranging from 2 to 20lM in 0.2M Tris-HCl
(pH 7.4). The reactions were incubated for 4 h at 37C resulting in maximum
formation of GS-1#-oxoestragole. The peak area of GS-1#-oxoestragole in the
chromatograms of these reactions were related to the quantity of GSH used in
the reactions. This could be done because, according to both LC-MS analysis as
well as HPLC analysis of the reaction mixture of GSH with 1#-oxoestragole,
only one product is formed and there is no residual GSH (determined using
a GSH assay kit), indicating that all GSH has reacted and that, thus, the
concentration of the adduct formed equals the original GSH concentration.
Kinetic analysis. The estragole concentration dependent rate of formation
of different phase I metabolites and the 1#-hydroxyestragole concentration
dependent glucuronidation and formation of 1#-oxoestragole were fitted to the
standard Michaelis-Menten equation:
v ¼ Vmax=ð1þ ðKm=½SÞÞ
with [S] being the substrate concentration. The apparent maximum velocity
(Vmax(app)), the apparent Michaelis-Menten constant (Km(app)), and the catalytic
efficiency Vmax(app)/Km(app) were determined, using the Life Science Work-
bench data analysis toolbox (version 1.1.1, MDL Information Systems, Inc.
(San Leandro, CA)).
PBBK model. A PBBK model for estragole in human was developed
based on the in vitro metabolic data. The model structure is similar to the
structure of the PBBK model previously developed for estragole in male rat
(Punt et al., 2008), and includes compartments for blood, liver, lung, kidney,
fat, rapidly perfused tissue, and slowly perfused tissue. The lung and kidney
compartment were added to obtain an equal structure of the model compared
with the previously developed model for estragole in male rat (Punt et al.,
2008). However, no specific reactions for absorption, metabolism, or excretion
were defined in these compartments because, in contrast to rat samples, human
microsomal incubations revealed no significant phase I metabolism of estragole
in these tissues. A schematic diagram of the human PBBK model is shown in
Figure 2. The physiological parameters and partition coefficients used in the
model are given in Table 1. The physiological parameters were obtained from
Brown et al. (1997). The partition coefficients were estimated from the log Kow
based on a method of DeJongh et al. (1997). Log Kow values were estimated
with the software package ClogP version 4.0 (Biobyte, Claremont, CA), and
amounted to 3.1 for estragole and 1.6 for 1#-hydroxyestragole.
Based on in vitro conversion data (see Results section), conversion of
estragole to 4-allylphenol, 1#-hydroxyestragole, estragole-2#,3#-oxide, and 3#-
hydroxyanethole was described in the liver compartment. The apparent in vitro
Vmax values for these reactions, expressed as nmol min
1 (mg microsomal
protein)1, were scaled to the liver using a microsomal protein yield of 32 mg/g
liver (Barter et al., 2007). The apparent in vitro Km values were assumed to
correspond to the apparent in vivo Km values. The uptake of estragole from the
gastrointestinal tract was described by a first-order process, assuming direct
entry from the intestine to the liver compartment. The absorption rate constant
(ka) was 1.0 /h. Mass balance equations for estragole in the liver were similar to
those described previously in the PBBK model for estragole in male rat (Punt
et al., 2008).
In the case of 4-allylphenol, estragole-2#,3#-oxide, and 3#-hydroxanethole
only formation of these metabolites are taken into account, and no further
reactions with these metabolites were modeled. Formation of 1#-hydroxyes-
tragole was followed by additional metabolic reactions. To this end a near
quantitative intrahepatic conversion of 1#-hydroxyestragole was assumed. This
assumption was based on the findings that the overall catalytic efficiency for the
reactions converting 1#-hydroxyestragole was higher than the catalytic
efficiency for the formation of 1#-hydroxyestragole. This simplification of the
model reduced the number of parameters considerably. Confining 1’-hydrox-
yestragole to the liver did not affect the relative formation of different metabolites
or the area under the concentration time-curve of 1’-hydroxyestragole in the liver.
The kinetic constants for glucuronidation of 1#-hydroxyestragole and formation
of 1#-oxoestragole were determined in the present study, whereas the kinetic
constants for sulfonation of 1#-hydroxyestragole were obtained from Punt et al.
(2007). The apparent in vitro Vmax values for glucuronidation and formation of
1#-oxoestragole, expressed as nmol min1 (mg microsomal protein)1, were
scaled to the liver using a microsomal protein yield of 32 mg per g liver (Barter
et al., 2007). The apparent in vitro Vmax value for sulfonation of
1#-hydroxyestragole, expressed as nmol min1 (mg S9 protein)1, were scaled
to the liver using an S9 protein yield of 143 mg/g liver (Medinsky et al., 1994).
Mass balance equations for 1#-hydroxyestragole in the liver were similar to those
described previously in the PBBK model for estragole in male rat (Punt et al.,
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2008), with the addition of oxidation of 1#-hydroxyestragole as additional
metabolic route by adding the following term to the equation describing the rate
of change in amount of 1#-hydroxyestragole in the liver compartment (dALHE/dt):
Vmax;LOE3CLHE=PLHE=

Km;LOE þ CLHE=PLHEÞ
where ALHE is the amount of 1#-hydroxyestragole in the liver (lmol), CLHE
is the 1#-hydroxyestragole concentration in the liver (lmol/l), PLHE is the
liver:blood partition coefficient of 1#-hydroxestragole, and Vmax,L_OE and
Km,L_OE are the maximum rate of formation and the Michaelis-Menten constant
for the formation 1#-oxoestragole in the liver.
Model equations were coded and numerically integrated in Berkeley
Madonna 8.0.1 (Macey and Oster, UC Berkeley, CA), using the Rosenbrock#s
algorithm for stiff systems. With the model obtained, predictions were made on
the time-dependent concentrations of estragole and 1#-hydroxyestragole in
human liver. In addition, predictions were made on the formation of different
metabolites of both estragole and 1#-hydroxyestragole after 24 h (expressed as
nmol/kg bw or percentage of the dose) following oral exposure to 0.07 mg/kg
bw estragole and in case of 1#-sulfooxyestragole also at different oral dose
levels. Additional predictions were made on the systemic bioavailability of
estragole as an indication of the systemic levels of estragole available for
extrahepatic metabolic conversion. The systemic bioavailability (BIO) of
estragole was defined using the following equation:
BIOð%Þ ¼ Dose ði:v:Þ=Dose ðoralÞ3AUC ðoralÞ=AUC ði:v:Þ3 100
where AUC0–24 (oral dose) is the area under the concentration-time curve of
the venous blood compartment after an oral dose of 0.07 mg/kg bw and
AUC0–24 (i.v. dose) is the area under the concentration-time curve of the
venous blood compartment after an intravenous dose of 0.07 mg/kg bw. The
intravenous dose was applied in the venous blood compartment over a time
period of 0.01 h.
Sensitivity analysis. A sensitivity analysis was performed to evaluate the
relative effect of model parameters on the model output. Normalized sensitivity
coefficients (SCs) were determined for the model parameters according to the
following equation:
SC ¼ C#  C=P#  P3 P=C
where C is the initial value of the model output, C# is the modified value of the
model output resulting from an increase in parameter value, P is the initial
parameter value, and P# is the modified parameter value (Evans and Andersen,
2000). Based on the literature (Evans and Andersen, 2000) a 5% increase in
parameter value was chosen to analyze the effect of a change in parameter value
on the amount of 1#-hydroxyestagole and 1#-sulfooxyestragole (expressed as
nmol/kg bw) formed over 24 h. Each parameter was analyzed individually,
keeping the other parameters to their initial values. SCs were calculated for all
physiological parameters (bw, tissue volumes, and blood flow rates), partition
coefficients, and biochemical parameters (Km and Vmax values for the different
metabolic reactions and ka).
Results
Conversion of Estragole: Phase I Metabolism
HPLC analysis of incubations with human liver, lung,
kidney, and small intestine microsomes in the presence of
estragole as substrate and NADPH as cofactor reveals that
conversion of estragole to phase I metabolites only occurs in
incubations with human liver microsomes (Fig. 3A). No
conversion of estragole is observed in incubations with
microsomes from the other organs (data not shown). In the
chromatograms of the incubations with human liver micro-
somes the peaks at 18.9, 20.6, and 39.6 min were identified as
1#-hydroxyestragole, 3#-hydroxyanethole, and 4-allylphenol
on the basis of comparison of the retention times and UV
spectra to the chemically synthesized reference compounds.
The peak at 9.1 min was previously identified as estragole-
2#,3#-diol (Punt et al., 2008), which is formed upon hydrolysis
of estragole-2#,3#-oxide due to the presence of epoxide
hydrolases in human liver microsomes (Guenthner and Luo,
2001; Luo et al., 1992).
Figure 3B shows the rate of formation of 1#-hydroxyestra-
gole, estragole-2#,3#-oxide, 3#-hydroxyanethole, and 4-allyl-
phenol in incubations with human liver microsomes with
increasing estragole concentrations. Table 2 summarizes the
apparent Km and Vmax values obtained from these plots as well
as the catalytic efficiencies, calculated as Vmax/Km. In the
FIG. 2. Schematic diagram of the proposed PBBK model for estragole in human. The lung and kidney compartments were included in the model to obtain an
equal structure of the model compared with the previously developed model for estragole in male rat (Punt et al., 2008). However, no specific reactions for
absorption, metabolism, or excretion of estragole were defined for these compartments.
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incubations with human liver microsomes, the catalytic
efficiency for formation of 1#-hydroxyestragole was the
highest, followed by that for formation of estragole-2#,3#-
oxide and 3#-hydroxyanethole. Formation of 4-allylphenol was
the least efficient catalytic phase I conversion in these
incubations. The high catalytic efficiency for 1#-hydroxylation
of estragole is mainly due to a relatively low Km for this
reaction, which was respectively 4-, 14-, and 17-fold lower than
the Km for epoxidation, O-demethylation and 3#-hydroxylation.
Conversion of 1#-hydroxyestragole: Formation of
1#-hydroxyestragole Glucuronide
Formation of the glucuronosyl conjugate of 1#-hydroxyes-
tragole was analyzed in incubations with pooled human liver
microsomes. Figure 4A shows an HPLC-chromatogram of
such an incubation in the presence of 1#-hydroxyestragole as
substrate and UDPGA as cofactor and reveals the formation of
a metabolite of 1#-hydroxyestragole with a retention time of
18.9 min. Treatment of the sample with b-glucuronidase
resulted in complete elimination of this metabolite and
formation of a corresponding amount of 1#-hydroxyestragole
(data not shown). This enzymatic deconjugation with b-
glucuronidase together with LC-MS analysis of the metab-
olite, revealing a deprotonated molecule at m/z 339, which
corresponds to the theoretically expected mass of 1#-
hydroxyestragole glucuronide, confirms the formation of
1#-hydroxyestragole glucuronide. The 1#-hydroxyestragole
concentration dependent rate of formation of 1#-hydroxyes-
tragole glucuronide by human liver microsomes is displayed
in Figure 4B. The kinetic constants were obtained from the
graph by fitting the data to the standard Michaelis-Menten
equation, resulting in an apparent Km of 708lM and an
apparent Vmax of 0.3 nmol min
1 (mg microsomal protein)1.
TABLE 1
Physiological Parameters and Partition Coefficients Used in the
PBBK Model for Estragole in Human
Parameter Value
Body weight (kg)a 60
Tissue volumes (% body weight)a,b
Liver 2.6
Lungs 0.8
Kidneys 0.4
Fat 21.4
Rapidly perfused 4.2
Slowly perfused 54.3
Venous blood 5.92
Arterial blood 1.98
Cardiac output (l/h/kg bw0.74)a 15
Blood flow to tissue (% cardiac output)a
Liver 22.7
Kidneys 17.5
Fat 5.2
Rapidly perfused 29.8
Slowly perfused 24.8
Partition coefficients of estragolec
Liver:blood 6.5
Lung:blood 6.5
Kidey:blood 6.5
Fat:blood 105
Rapidly perfused:blood 6.5
Slowly perfused:blood 4.1
Partition coefficient of 1#-hydroxyestragoled
Liver:blood 1.6
aBrown et al. (1997).
bDoes not account for hair, nails, and gut and bladder content.
cDeJongh et al. (1997).
dUsed to determine the free concentration of 1#-hydroxyestragole in the liver
available for metabolism. FIG. 3. (A) Chromatographic profile of an incubation with human liver
microsomes at a substrate concentration of 400 lM estragole, NADPH as
cofactor and an incubation time of 10 min. Peaks marked with an asterisk were
also present in the blank incubations performed without cofactor NADPH, in
which they had the same area under the curve as in this incubation. (B)
Estragole concentration dependent rate of formation of phase I metabolites by
human liver microsomes. In the plots each point represents the mean (± SD) of
three replicates corresponding to the formation of respectively 1#-hydroxyes-
tragole (filled triangle), estragole-2#,3#-oxide (x), 3#-hydroxyanethole (filled
square), and 4-allylphenol (filled circle).
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Conversion of 1#-hydroxyestragole: Formation of
1#-oxoestragole
In addition to conjugation reactions of 1#-hydroxyestragole
the occurrence of oxidation of 1#-hydroxyestragole to 1#-
oxoestragole was examined. Formation of this metabolite was
observed in incubations with human liver microsomes using
NADþ as cofactor and GSH to trap the transient 1#-
oxoestragole. Figure 5A shows a HLC-chromatogram of such
an incubation. The peak at 7.9 min was identified as GS-1#-
oxoestragole on the basis of comparison of the retention time
and UV spectrum to the chemically synthesized GS-1#-
oxoestragole. Furthermore the mass spectrum of the metabolite,
obtained by LC-MS, reveals a protonated molecule at m/z 470,
which corresponds to the theoretically expected mass and this
confirms formation of GS-1#-oxoestragole in the incubation.
The peak was not present in the incubations without GSH or
blank incubations without microsomes or cofactor (data not
shown). Because the occurrence of this reaction was previously
not analyzed for male rat (Punt et al., 2008), additional
incubations were performed to determine formation of 1#-
oxoestragole by male rat liver microsomes as well. Figure 5B
reveals the 1#-hydroxyestragole concentration dependent
formation of 1#-oxoestragole by human and male rat liver
microsomes as determined by quantification of the GS-1#-
oxoestragole, which is assumed to represent the formation of
1#-oxoestragole. The Km for formation of 1#-oxoestragole by
human liver microsomes was determined to be 354lM and the
Vmax 4.9 nmol min
1 (mg microsomal protein)1. For
formation of 1#-oxoestragole by rat liver microsomes the Km
was determined to be 1609 lM and the Vmax 2.9 nmol min
1
(mg microsomal protein)1.
Comparison of the Kinetic Data for Estragole Bioactivation
and Detoxification by Human and Male Rat Tissue
Fractions
Table 3 presents a summary of the kinetic parameters for
estragole bioactivation and detoxification by human tissue
fractions combined with the kinetic parameters previously
reported for male rat tissue fractions (Punt et al., 2007, 2008).
Available literature data on the kinetics for glucuronidation of
1#-hydroxyestragole by Iyer et al. (2003) were not included in
this comparison, because we have previously observed that
these data reflect kinetic constants for glucuronidation of 3#-
hydroxyanethole rather than glucuronidation of 1#-hydroxyes-
tragole (Punt et al., 2008).
In Table 3, the Vmax values expressed as lmol h
1 (g liver)1
were obtained by scaling of the in vitro Vmax values to Vmax
values expressed per g liver using microsomal and S9 protein
yields from the different organs that were obtained from the
literature (Barter et al., 2007; Medinsky et al., 1994). This
conversion allowed comparison of the kinetic constants obtained
with different tissue fractions. In the case of phase I metabolism
of estragole, comparison of the kinetic constants between
humans and male rats reveals that the catalytic efficiency (scaled
Vmax/Km) for formation of the proximate carcinogenic metabolite
1#-hydroxyestragole is 2.7-fold higher in human liver. Although
TABLE 2
Kinetic Parameters for Phase I Metabolism of Estragole by
Human Liver Microsomes
Metabolite Km(app)
a,b Vmax (app)
a,c
In vitro
catalytic efficiencyd
4-Allylphenol 290 ± 28 0.38 ± 0.02 1.3
1#-Hydroxyestragole 21 ± 6 0.73 ± 0.04 34.8
3#-Hydroxyanethole 350 ± 20 1.35 ± 0.05 3.9
Estragole-2#,3#-oxide 83 ± 17 0.85 ± 0.07 10.2
aMean ± SE.
blM.
cnmol min1 (mg microsomal protein)1.
dll min1 (mg microsomal protein)1 (Vmax (app)/Km(app) 3 1000 ll/ml).
FIG. 4. (A) Chromatographic profile of an incubation with human liver
microsomes at a substrate concentration of 500lM 1#-hydroxyestragole,
UDPGA as cofactor and an incubation time of 360 min. The peak marked with
an asterisk was also present in the blank incubation performed without cofactor.
(B) 1#-Hydroxyestragole concentration dependent rate of formation of 1#-
hydroxyestragole glucuronide by human liver microsomes. In the plot, each
point represents the mean (± SD) of three replicates.
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the Vmax for 1#-hydroxylation is twofold lower in human liver,
the Km is 5.5-fold lower resulting in a higher overall catalytic
efficiency. The catalytic efficiencies for O-demethylation and
epoxidation of estragole are similar for human and male rat liver,
but the catalytic efficiency for 3#-hydroxylation of estragole is
threefold lower in human liver. This lower observed catalytic
efficiency is mainly due to a 3.8-fold higher Km for
3#-hydroxylation in human liver. Another important difference
between human and male rat is that no detoxifying
O-demethylation occurs in human lung and kidney, whereas
this metabolic route occurs with high affinity in male rat lung and
kidney.
With respect to the metabolic reactions with 1#-hydroxyes-
tragole, the catalytic efficiency for formation of the ultimate
carcinogenic metabolite, 1#-sulfooxyestragole was previously
found to be 30-fold lower in human liver compared with male
rat liver (Table 3) (Punt et al., 2007). Comparison of the
catalytic efficiency for glucuronidation of 1#-hydroxyestragole
by human and male rat liver samples reveals that this metabolic
route is more than 438 times less efficient in the human liver,
which is mainly due to an 100-fold lower Vmax for
glucuronidation in human liver. Oxidation of 1#-hydroxyestra-
gole is found to be a major metabolic route in human liver.
Comparison of the catalytic efficiency for formation of 1#-
oxoestragole by human and male rat liver samples reveals that
this metabolic route is 9-fold more efficient in the human liver,
which can be explained by both a 1.7-fold higher Vmax value
and a 4.5-fold lower Km value for 1#-hydroxyestragole
oxidation in human liver.
Human PBBK Model
Based on the in vitro kinetic data for bioactivation and
detoxification of estragole by human tissue fractions a PBBK
model for estragole in human was developed. Figure 6 displays
the time-dependent predicted concentrations of estragole in
plasma and liver and the time-dependent predicted concen-
trations of 1#-hydroxyestragole in the liver following oral
exposure to 0.07 mg/kg bw estragole, which corresponds to the
average dietary human intake as estimated by the SCF (2001).
The PBBK model predicts that both estragole and 1#-
hydroxyestragole are metabolized within the 24-h timeframe.
Accumulation of estragole or its reactive metabolites is
therefore not expected to occur when a repeated dosing would
be applied after 24 h. With the model obtained, estimations
were made on the formation of different metabolites (Table 4).
The major part of estragole is converted to 1#-hydroxyestragole
(304 nmol/kg bw, corresponding to 64.4% of the dose). This
metabolite is in turn predominantly converted to 1#-oxoestra-
gole (294 nmol/g liver, corresponding to 62.3% of the dose).
Due to this high level of formation of 1#-oxoestragole,
formation of the ultimate carcinogenic metabolite, 1#-sulfoox-
yestragole is relatively low, with only 0.19% of the dose being
converted to this metabolite.
Estimation of the formation of the proximate carcinogenic
metabolite 1#-hydroxyestragole at different oral doses revealed
that the relative formation of this metabolite decreases with
increasing dose due to saturation of this metabolic route.
However, the observed relative decrease in formation of 1#-
hydroxyestragole was not substantial at doses relevant for
dietary human intake, given that at a dose of 0.7 mg/kg bw
(i.e., 10-fold higher than the estimated average dietary human
intake), the percentage of the dose that is ultimately converted
to 1#-hydroxyestragole is similar (63.9%) to the one at a dose
of 0.07 mg/kg bw (64.4%). Only when a dose of 10 mg/kg bw
is applied (i.e., 150-fold higher than the average dietary human
intake) a decrease of approximately 10% of the percentage of
the dose converted to 1#-hydroxyestragole was observed
leading to a value of 56.9%. The relative decrease in formation
of 1#-hydroxyestagole with increasing doses resulted in
a concomitant decrease in formation of 1#-sulfooxyestragole,
FIG. 5. (A) Chromatographic profile of an incubation with human liver
microsomes at a substrate concentration of 500lM 1#-hydroxyestragole, NADþ
as cofactor and GSH to trap the transient 1#-oxoestragole at an incubation time
of 10 min. (B) 1#-Hydroxyestragole concentration dependent rate of formation
of 1#-oxoestragole by human (filled triangle) and male rat (filled circle) liver
microsomes as determined by quantification of the GS-1#-oxoestragole, which
is assumed to represent the formation of 1#-oxoestragole. In the plots each point
represents the mean (± SD) of three replicates.
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1#-hydroxyestragole glucuronide, and 1#-oxoestragole amount-
ing to respectively 0.19, 1.9, and 61.8% of the dose at 0.7 mg/
kg bw and to 0.17, 1.7, and 55.0% of the dose at 10 mg/kg bw.
The performance of the PBBK model defined for estragole
in human could, to some extent, be evaluated against
available in vivo data on the disposition of 0.001 mg/kg bw
[methoxy-14C]-labeled estragole in two human volunteers
obtained from Sangster et al. (1987). In this disposition study
of estragole in humans, ~10% of the dose was excreted as
14CO2 after 8 h, corresponding to the level of O-demethyla-
tion of estragole. The major part of the radioactivity (31–37%
of the dose after 8 h, 47–53% after 24 h, and 54–62% after
48 h) was excreted in the urine, corresponding to metabolites
arising from various oxidations of the side chain (Sangster
et al., 1987). Structural analysis of the urinary metabolites
revealed ~0.4% of the dose being excreted as 1#-hydrox-
yestragole glucuronide. For evaluation of the model
performance, the PBBK-model predicted formation of 1#-
hydroxyestragole glucuronide and 4-allylphenol, at an oral
TABLE 3
Kinetic Constants for Estragole Metabolism by Human and Male Rat Tissue Fractions
Humana Male ratb
Metabolite Organ Scaled Vmax (app)
c Km (app)
d Catalytic efficiencye Scaled Vmax (app)
c Km (app)
d Catalytic efficiencye
estragole metabolites
4-allylphenol Liver 0.7 290 2 1.6 458 3
Lung n.d.f n.d. – 0.8 0.5 1600
Kidney n.d. n.d. – 0.2 0.5 400
1#-hydroxyestragole Liver 1.4 21 67 2.8 116 24
Lung n.d. n.d. – 0.5 26 18
Kidney n.d. n.d. – 0.1 22 4
3#-hydroxyanethole Liver 2.6 350 7 2.0 93 22
estragole-2#,3#-oxide Liver 1.6 83 19 4.1 154 27
1#-hydroxyestragole metabolites
1#-sulfooxyestragole Liver 0.06 727 0.1 0.2 63 3
1#-hydroxyestragole glucuronide Liver 0.6 708 1 60 137 438
1#-oxoestragole Liver 9.4 354 27 5.6 1609 3
aData obtained from present study and Punt et al. (2007).
bData obtained from Punt et al. (2007), Punt et al. (2008) and in the case of 1#-oxoestragole from the present study.
cScaled Vmax (app) expressed as lmol h
1 (g tissue)1, calculated from the in vitro Vmax (app) based on a microsomal protein yield of 32, 20, and 7 mg/g tissue for
liver, lung, and kidney respectively, and an S9 protein yield of 143 mg/g liver.
dKm(app) expressed as lM.
eCatalytic efficiency (scaled Vmax (app)/Km(app)) expressed as ml h
1 (g liver)1.
fn.d. ¼ not detectable.
FIG. 6. PBBK-model predicted time dependent concentrations of estragole
in plasma and liver and the time-dependent predicted concentrations of 1#-
hydroxyestragole in the liver following exposure to 0.07 mg/kg bw estragole.
TABLE 4
PBBK-model Predicted Quantities of Metabolites Formed
During 24 h After an Oral Dose of 0.07 mg/kg bw (472 nmol/kg bw)
Metabolite Amount formed (nmol/kg bw)
Estragole metabolites
4-Allylphenol 12
1#-Hydroxyestragole 304
3#-Hydroxyanethole 34
Estragole-2#,3#-oxide 90
1#-Hydroxyestragole metabolites
1#-Hydroxyestragole glucuronide 9
1#-Oxoestragole 294
1#-Sulfooxyestragole 0.9
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dose of 0.001 mg/kg bw, were compared with the reported
levels of these metabolites. To this end it was assumed that
formation of 1#-hydroxyestragole glucuronide equals excre-
tion of this metabolite in the urine, whereas formation of 4-
allylphenol is assumed to correspond to the reported level of
exhalation of 14CO2. The PBBK-model predicted formation of
1#-hydroxyestragole glucuronide, corresponding to 1.9% of the
dose after 24 h, is 5-fold higher than the reported in vivo level
of this metabolite of ~0.4%. The predicted formation of 4-
allylphenol, corresponding to 2.4% of the dose after 8 h, is
fourfold lower than the reported in vivo level of ~10% of the
dose after 8 h (Sangster et al., 1987). These results indicate that
the PBBK model predicts the formation of these metabolites
within the same order of magnitude as the reported levels.
Formation of the major metabolite, 1#-oxoestragole, could not
be evaluated against human in vivo data, since excretion of 1#-
oxoestragole as GSH or protein adducts was not analyzed in
humans exposed to estragole (Sangster et al., 1987).
Sensitivity Analysis
The sensitivity of the predicted formation of 1#-hydroxyes-
tragole and 1#-sulfooxyestragole to changes in all model
parameters was analyzed to identify the key parameters in the
human model that influence bioactivation of estragole.
Normalized SCs were calculated at a dose of 0.07 mg/kg bw
estragole, but only parameters that had a normalized SC higher
than 0.1 (in absolute value) are displayed in Figure 7.
Formation of 1#-hydroxyestragole is influenced by the kinetic
constants for 1#-hydroxylation of estragole in the liver and to
a minor extent also by the kinetic constants for epoxidation,
which is the most important competing metabolic pathway to
1#-hydroxylation in the liver. In the case of 1#-sulfooxyestra-
gole, the predicted formation of this metabolite depends on the
parameters that determine the formation of 1#-hydroxyestra-
gole, but formation of this metabolite is predominantly
influenced by the kinetic constants for the formation of 1#-
oxoestragole and the kinetic constants for formation of
1#-sulfooxyestragole itself. This indicates that oxidation of
1#-hydroxyestragole is an important competing metabolic
pathway to sulfonation due to its higher catalytic efficiency.
Physiological parameters (bw, tissue volumes, and blood flow
rates) and partition coefficients do not significantly affect the
relative extent of formation of 1#-hydroxyestragole and
1#-sulfooxyestragole in human liver. Differences in, for
instance, estimated tissue:blood partition coefficients between
human and rat will therefore not affect the comparison between
these species in formation of 1#-hydroxyestragole and
1#-sulfooxyestragole.
Comparison of the PBBK-Model Predicted Plasma and
Tissue Levels of Estragole and 1#-hydroxyestragole
between Human and Male Rat
To obtain insight in possible species differences in metabolic
activation and detoxification of estragole between human and
male rat, the results obtained with the PBBK model for
estragole in human were compared with those of the previously
defined PBBK model for estragole in male rat (Punt et al.,
2008). Because the formation of 1#-oxoestragole from 1#-
hydroxyestragole was previously not described in the PBBK
model for male rat, the rat model was adjusted by the addition
of this metabolic route using the kinetic data obtained in the
present study to allow equal comparison between the rat and
human model.
The predicted AUC0–24h of estragole in plasma is predicted
to be fourfold higher for human than for male rat (Fig. 8). This
can be explained by the higher overall clearance of estragole in
rat due to significant extrahepatic metabolism of estragole in
male rat lung and kidney (Punt et al., 2008), which does not
occur in human lung and kidney. Comparison of the predicted
AUC0–24h of estragole in the liver between human and male rat
reveals that the AUC0–24h is sixfold higher in human. This is
the result of a threefold higher value of the estimated partition
coefficient of estragole in human liver. This phenomenon has
previously been attributed to a higher solubility of lipophilic
compounds in rat blood over human blood, which is assumed
to be a result of species differences in the hemoglobin structure
(Lam et al., 1990; Wiester et al., 2002). In case of 1#-
hydroxyestragole, the AUC0–24h of this metabolite in the liver
is predicted to be 144-fold higher in human than in male rat,
which can be explained by a higher level of formation of this
metabolite as well as a lower metabolic clearance of this
metabolite in human liver. Overall, the differences in plasma
and liver levels of estragole and liver levels of 1#-hydroxy-
estragole indicate that the turnover of both estragole and 1#-
hydroxyestragole is relatively lower in human compared with
FIG. 7. Sensitivity of the predicted formation of 1#-hydroxyestragole
(black bars) and 1#-sulfooxyestragole (gray bars) to different model parameters.
The Vmax and Km correspond to the maximum rate of formation and the
Michaelis-Menten constant for the formation of the different metabolites in the
liver: 1#-hydroxyestragole (HE), estragole-2#,3#-oxide (EE), 1#-oxoestragole
(OE) and 1#-sulfooxyestragole (HES).
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male rat. These differences in turnover will affect the time-
frame in which various metabolites are formed, but does not
affect the relative levels, at which different metabolites are
formed when metabolic conversion is completed.
Comparison of the PBBK-Model Predicted Formation of
Metabolites between Human and Male Rat
Comparison of the PBBK-model predicted formation of
different metabolites will provide an indication of the relative
extent of bioactivation and detoxification of estragole. The
evaluation of species differences in the formation of various
metabolites, presented hereafter, is first focused on dose levels
relevant for dietary human intake. In addition, a comparison is
made between human and male rat in the predicted formation
of 1#-sulfooxyestragole at different oral doses.
In Figure 9A the predicted formation of phase I metabolites
(expressed as percentage of the dose) in human and male rat
following an oral dose of 0.07 mg/kg bw estragole is displayed.
A major difference between humans and male rats occurs in the
formation of 4-allylphenol, which is predicted to be 24-fold
lower in humans. This observed difference is due to the effect
of extrahepatic metabolism on the formation of this metabolite,
occurring in male rat (Punt et al., 2008) but not in human. In
male rat, first pass metabolism of estragole in the liver is
relatively low, resulting in a relatively high systemic bio-
availability of estragole, which is predicted to amount to 57%
at a dose of 0.07 mg/kg bw. Extrahepatic conversion of
estragole is therefore possible. Metabolism in the lung and
kidney contribute significantly to the extent of O-demethyla-
tion of estragole in male rat, since this reaction occurs in these
organs with high affinity (Punt et al., 2008). In humans,
systemic availability of estragole is predicted to be 32% at
a dose of 0.07 mg/kg bw, which is lower than in male rat. But
more importantly, no detoxifying O-demethylation, or other
phase I metabolic reactions occur in human lung and kidney.
Due to the lower extent of O-demethylation as well as a higher
efficiency for 1#-hydroxylation in human, the formation of 1#-
hydroxyestragole is observed to be fourfold higher in human
compared with male rat. Formation of 3#-hydroxyanethole and
estragole-2#,3#-oxide are similar in the two species.
Figure 9B displays the metabolites formed from 1#-
hydroxyestragole in human and male rat. The greater part of
the 1#-hydroxyestragole that is formed in human is oxidized to
1#-oxoestragole, which is due to the relative high efficiency for
oxidation of 1#-hydroxyestragole in comparison to glucuroni-
dation and sulfonation. When the oxidation of 1#-hydroxyes-
tragole is added to the rat PBBK model, the model predicts low
formation of this metabolite at a level corresponding to 0.1% of
the dose. This is due to the fact that the catalytic efficiency for
the formation of 1#-oxoestragole in male rat is much lower in
comparison to glucuronidation of 1#-hydroxyestragole. In male
rat 1#-hydroxyestragole is almost completely metabolized to
1#-hydroxyestragole glucuronide. Comparison of the predicted
formation of the ultimate carcinogenic metabolite between
human and male rat reveals that the predicted overall formation
of 1#-sulfooxyestragole is approximately twofold higher in
human liver at an oral dose of 0.07 mg/kg bw.
Because dose-dependent effects in bioactivation and de-
toxification can affect the level of species differences at
different oral doses, a comparison needs to be made on the
predicted formation of 1#-sulfooxyestragole at different oral
doses between human and male rat. The predicted formation of
1#-sulfooxyestragole, expressed as nmol/kg bw, within a dose
range of 105 mg/kg bw and 103 mg/kg bw is depicted in
Figure 10. Both curves are observed to be quite linear up to
doses as high as 100 mg/kg bw, when plotted on a log-log scale
as done in Figure 9 as well as on a linear scale (not shown). In
case of male rat, the previously predicted relative increase in
formation of 1#-sulfooxyestragole with increasing doses (Punt
et al., 2008) is not significant enough to result in large species
differences at higher dose levels. In case of human, saturation
of the 1#-hydroxylation pathway at doses higher than 100 mg/
kg bw results in a decrease in the relative formation of 1#-
sulfooxyestragole with increasing doses. At these dose levels,
formation of 1#-sulfooxyestragole becomes relatively lower in
human compared with male rat.
Discussion
A PBBK model for estragole metabolism in human was
defined based on in vitro kinetic data, providing possibilities to
evaluate the relative extent of different metabolic routes at dose
levels relevant for dietary human intake. With the model
obtained, the occurrence of species differences in metabolic
activation of estragole was evaluated by comparison of the
FIG. 8. PBBK-model predicted area under the concentration-time curve
(AUC0–24h) for estragole in plasma and liver (A) and 1#-hydroxyestragole (B)
in human (black bars) and male rat (gray bars) in the liver following exposure
to 0.07 mg/kg bw estragole.
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outcomes of the defined model with those of the previously
defined PBBK model for estragole in male rat (Punt et al.,
2008).
The performance of the human PBBK model was evaluated
by comparing the predicted formation of 4-allylphenol and 1#-
hydroxyestragole glucuronide to the reported levels of these
metabolic routes in humans exposed to a single oral dose of
estragole (Sangster et al., 1987). The predicted formation of 4-
allylphenol and 1#-hydroxyestragole glucuronide were in the
same order of magnitude as the reported levels of these
metabolic routes in humans exposed to estragole (Sangster
et al., 1987), which can be considered acceptable within the
present state-of-the-art of integrating in vitro data and PBBK
modeling (Hissink et al., 1997; Lupfert and Reichel, 2005;
Quick and Shuler, 1999), and which might provide an
indication that the critical metabolic pathways have been
captured in the model. For a more complete evaluation of the
performance of the model, however, additional in vivo data are
needed, especially on the plasma levels of estragole and/or its
metabolites. Overall, it should be stated that the present model
derived from integrating in vitro metabolic data using PBBK
modeling as a platform, does not allow conclusions based on
absolute outcomes. However, the relative importance of
different metabolic pathways in humans can be predicted and
moreover a relative comparison of species differences in the
extent of bioactivation and detoxification can be made, since
the in vitro metabolic data for human and male rat are obtained
with similar methods.
Based on the approach of identifying principal metabolic
pathways of estragole in incubations with human tissue
fractions, the present study revealed that oxidation of 1#-
hydroxyestragole can be a main detoxification route of 1#-
hydroxyestragole in humans. Formation of the major metab-
olite 1#-oxoestragole could, however, not be evaluated against
human in vivo data, because excretion of this metabolite or its
conjugates was not analyzed in humans exposed to estragole
(Sangster et al., 1987). In this study on humans exposed to
estragole (Sangster et al., 1987), the greater part of the urinary
metabolites (36–44% of the oral dose) could not be identified
due to insufficient knowledge of the nature of the excreted
metabolites. In addition, a significant proportion of ~30% of
the radioactivity was not recovered within 48 h (Sangster et al.,
1987). It was suggested by the authors that this incomplete
recovery of radioactivity could be due to premature termination
of the collection of exhaled 14CO2 after 8 h, suggesting that
metabolic conversion of estragole is not complete within this
time-frame (Sangster et al., 1987). The outcomes of the PBBK
model of the present study indicate, however, that metabolic
FIG. 9. PBBK-model predicted formation of phase I metabolites in human
(black bar) and male rat (gray bar) following an oral dose of 0.07 mg/kg bw
estragole (A) and the metabolites formed from 1#-hydroxyestragole in human
and male rat at this oral dose (B).
FIG. 10. PBBK model-predicted dose-dependent formation of 1#-sulfooxy-
estragole in the liver of rat (—) and human (- -).
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conversion of estragole is essentially complete within 8 h and
might suggest another reason for incomplete recovery of
radioactivity, which could, for instance, be due to enterohepatic
circulation of metabolites. Overall, the large proportion of
unidentified metabolites in humans might reflect the formation
of 1#-oxoestragole, which was predicted to amount to 62.7% of
the dose, based on the PBBK model for estragole in human
developed in the present study. Obviously, the relevance of the
oxidation pathway of 1#-hydroxyestragole in humans needs to
be further confirmed in vivo.
Although the extent of oxidation of 1#-hydroxyestragole to
1#-oxoestragole could not be evaluated against human in vivo
data, evidence for the presence in vivo of the oxidation route of
1#-hydroxyestragole can be found in experiments with rats
exposed to estragole or other alkenylbenzenes. Solheim and
Scheline (1973) described the excretion of small amounts of
amino conjugates in rats exposed to estragole, which were
assumed to originate from 1#-oxoestragole. In the case of the
related alkenylbenzene safrole, Fennell et al. (1984) described
the excretion of GS-1#-oxosafrole and N-acetylcystein-1#-
oxosafrole in rats exposed to the 1#-hydroxy metabolite of this
compound, indicating formation of 1#-oxo metabolites in these
rats. The excretion of 1#-oxosafrole conjugates was however
relatively low in comparison to the excretion of glucuronosyl
conjugates of 1#-hydroxysafrole, which is in agreement with
results of the present study revealing that the predicted
formation of 1#-oxoestragole is relatively low and of minor
importance in male rat in comparison to the predicted
glucuronidation of 1#-hydroxyestragole. Although 1#-oxoes-
tragole can potentially react with DNA (Phillips et al., 1981),
this metabolite, which is a soft acid, is not expected to
contribute to the genotoxicity of estragole in vivo, since it can
readily react with glutathione (soft base) rather than with DNA
molecules (hard bases) (Fennell et al., 1984). This is supported
by literature data revealing that 1#-oxoestragole is not
carcinogenic in vivo in mice (Wiseman et al., 1987). For this
reason formation of 1#-oxoestragole in human can be
considered as the major detoxification pathway of 1#-
hydroxyestragole.
Comparison of the predicted extent of bioactivation of
estragole between humans and male rats at a dose of 0.07 mg/
kg bw showed that the formation of the proximate carcinogenic
metabolite 1#-hydroxyestragole is fourfold higher in human
liver compared with male rat liver, which is mainly due to the
relatively lower extent of detoxification of estragole through
O-demethylation in human. This observation that O-demethy-
lation of estragole is a less important metabolic route in
humans than in rats is supported by in vivo data showing that
only ~10% of the oral dose was excreted through this
metabolic route in humans at a dose of 0.001 mg/kg bw
(Sangster et al., 1987), whereas in rats this metabolic route
accounted for 53% of the oral dose at a comparable dose level
of 0.05 mg/kg bw (Anthony et al., 1987). The relatively high
formation of the O-demethylated metabolite 4-allylphenol in
male rats at low dose levels has previously been demonstrated
to be due to extrahepatic formation of 4-allylphenol in lung and
kidney tissue of male rat at low oral doses of estragole (Punt
et al., 2008). Such a high level of extrahepatic metabolism of
estragole in male rat is possible due to a relatively high
systemic bioavailability of estragole and the capacity of the
lung and kidney tissue to catalyze O-demethylation of estragole
with a high affinity (Punt et al., 2008).
No detoxifying O-demethylation or other phase I metabolic
reactions were observed to occur in human lung and kidney
tissue samples. The absence of phase I metabolism in human
lung and kidney can be rationalized when the P450 enzymes
involved are not expressed in these tissues. Jeurissen et al.
(2007) recently identified that P450 1A2 and P450 2A6 play
a pivotal role in estragole 1#-hydroxylation. These enzymes are
absent or only poorly expressed in human lung and kidney
(Pelkonen and Raunio, 1997; Shimada et al., 1996), which is in
line with the observation that no significant 1#-hydroxylation
activity occurs in the corresponding tissue fractions. The P450
enzymes involved in O-demethylation have not been identified
so far, but if it would be assumed that similar P450 enzymes as
for 1#-hydroxylation are involved, this would explain that
overall no phase I metabolism is detected in human lung and
kidney tissue.
Mainly due to a lower level of O-demethylation of estragole
in human compared with male rat, the predicted formation of
1#-hydroxyestragole (expressed as percentage of the dose) is
fourfold higher in human. Even though formation of 1#-
hydroxyestragole is fourfold higher, the formation of the
ultimate carcinogenic metabolite, 1#-sulfooxyestragole is
predicted to be only twofold higher in human. This can be
explained by the fact that the major part of 1#-hydroxyestragole
is oxidized to 1#-oxoestragole in human, due to a relative high
catalytic efficiency for oxidation of 1#-hydroxyestragole. The
twofold higher predicted formation of 1#-sulfooxyestragole in
human as compared with rat liver was consistent over a dose-
range from 105 to 102 mg/kg bw. At higher doses the
predicted formation of 1#-sulfooxyestragole can become 1.5 to
2-fold lower in human compared with male rat, mainly due to
saturation of the 1#-hydroxylation pathway of estragole in
humans, which results in a concomitant apparent saturation of
the formation of 1#-sulfooxyestragole.
The observed species differences in bioactivation and
detoxification of estragole, outlined above, reflect differences
between male rat and an average human situation. Significant
interindividual variation might, however, occur due to genotype-
and lifestyle-based factors that influence the activity of enzymes
for the key metabolic reactions involved in bioactivation and
detoxification of estragole. Parameter sensitivity analysis of the
predicted formation of 1#-sulfooxyestragole in humans revealed
that formation of this metabolite mainly depends on the kinetics
of formation of 1#-hydroxyestragole, subsequent oxidation of
1#-hydroxyestragole to 1#-oxoestragole, as well as the kinetics
of the formation of 1#-sulfooxyestragole itself. Knowledge about
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the enzymes involved in these reactions is essential to obtain
insight in the consequences of possible interindividual variation
in these enzymes. As indicated above, 1#-hydroxylation of
estragole is mainly catalyzed by P450 1A2 and 2A6 (Jeurissen
et al., 2007). The activities of these enzymes are known to be
significantly affected by genotype- and lifestyle-based factors
(Ingelman-Sundberg et al., 1999; Jiang et al., 2006). Additional
studies are currently being performed to identify enzymes
involved in other bioactivation and detoxification pathways of
estragole and to determine the effect of interindividual variability
in these metabolic reactions on the formation of the ultimate
carcinogen, 1#-sulfooxyestragole. In the safety assessment of
estragole these interindividual differences need to be taken into
account.
When extrapolating cancer data from high dose animal
experiments to the low dose human situation it is important to
take species differences in metabolism and metabolic activation
into account. Comparison of in vitro metabolic data for
estragole bioactivation and detoxification between human and
male rat, as done in the present study using PBBK modeling to
integrate these metabolic data, provides an approach that
allows to evaluate whether species differences in bioactivation
are to be expected. Overall it is shown that, even though
significant species differences in the relative extent of different
metabolic pathways occur between human and male rat, these
differences ultimately only result in a minor difference in the
PBBK model based predicted formation of 1#-sulfooxyestra-
gole at dose levels relevant for dietary human intake It is,
therefore, concluded that in spite of significant differences in
the catalytic efficiency of specific individual estragole bio-
transformation reactions there is a minor influence of species
differences between human and male rats on the ultimate
overall bioactivation of estragole to its ultimate carcinogenic
DNA reactive metabolite 1#-sulfooxyestragole.
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